Risks and limits of APOE Test

The APOE genetic test identifies the ε4 variant, which is associated with an increased risk for Alzheimer's disease. The evidence is strong: carriers of one ε4 allele have a 3- to 4-fold increased risk, and those with two ε4 alleles have a 10- to 15-fold increased risk. However, the test is not diagnostic – many ε4 carriers never develop Alzheimer's, and many Alzheimer's patients lack ε4. Key limits include low individual predictive value, lack of proven preventive treatments, and psychosocial risks such as anxiety, stigma, or false reassurance. A positive result may also affect insurance or employment. Major medical guidelines (e.g., from the DGN) recommend against routine predictive testing in asymptomatic individuals unless there is a strong family history. The test should only be offered with pre- and post-test genetic counseling. In summary, the APOE test provides useful risk information, but its clinical utility is limited, and the potential harms must be carefully weighed.